Your session is about to expire
← Back to Search
Staccato Alprazolam for Seizures
Study Summary
This trial will study the effects of taking Staccato alprazolam over a long period of time.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have or had acute narrow-angle glaucoma.I have mild asthma or other allergies affecting my breathing but can still participate.I have had a major seizure episode in the last 8 weeks.I regularly take opioids or sedatives.I am not allergic to the trial medication or similar drugs, including albuterol.I tested positive for COVID-19 and needed treatment for breathing problems.I have a serious lung condition other than mild asthma, or I've recently coughed up blood or had a collapsed lung.I am regularly taking medication that affects my heart and blood pressure.I had a severe cold or flu in the last 4 weeks or serious lung infection in the last 3 months.I am currently taking medication that strongly affects liver enzyme activity.I have seizures that might not be due to epilepsy.I have been diagnosed with epilepsy and have a history of long-lasting seizures.I have completed a study with Staccato alprazolam.You have had problems with alcohol or drug use in the past year.I cannot take alprazolam due to my health condition.I am 12 years old or older.
- Group 1: Staccato alprazolam
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA cleared Staccato alprazolam for use?
"There is robust clinical data attesting to the safety of Staccato alprazolam, as this medication has completed Phase 3 trials."
Do different hospitals offer this research opportunity to patients?
"30 different sites are currently running this trial, these include Ep0165 50364 in Philadelphia, Ep0165 50299 in New Brunswick, and Ep0165 50298 in New Orleans."
To the best of your knowledge, has there been a similar study like this one before?
"3 ongoing trials for Staccato alprazolam are taking place in 28 cities and 10 countries. The first one started in 2021 and completed Phase 3 in that same year. The sponsor of the trial, UCB Biopharma SRL, recruited 250 patients total. Since then, 57 more studies have been completed."
What are the projected benefits of this research?
"The purpose of this study, which will occur over the course of 48 months, is to observe the frequency of serious adverse events. Additionally, the study hopes to see treatment success rates after IMP administration for seizures occurring in the first 6 months and for seizures during the first 12 months with no recurrence after 2 hours. Finally, the study will also take note of the frequency of respiratory adverse events."
What other research has explored the effects of Staccato alprazolam?
"Currently, there are 3 ongoing studies involving Staccato alprazolam with 2 being in Phase 3. Although a large portion of the research is based in Lublin, New jersey, there are a total of 153 locations running trials."
Share this study with friends
Copy Link
Messenger